Merck KGaA

11/16/2026 | Press release | Distributed by Public on 11/16/2026 16:14

Tender Offer Statement (Form SC TO-C)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE TO

Tender Offer Statement Under Section 14(d)(1) or 13(e)(1)

of the Securities Exchange Act of 1934

RAPID MICRO BIOSYSTEMS, INC.

(Name of Subject Company (Issuer))

EMD HOLDINGS NEWCO II, INC

a wholly owned subsidiary of

MERCK KGAA

(Names of Filing Persons - Offerors)

Class A Common Stock, par value $0.01 per share

Class B Common Stock, par value $0.01 per share

(Title of Class of Securities)

75340L104

(CUSIP Number of Class of Securities)

Dr. Tina Sandmann

Merck KGaA

Frankfurter Strasse 250

64293 Darmstadt

Germany

+49 6151 720

(Name, Address and Telephone Number of Person Authorized to

Receive Notices and Communications on Behalf of Filing Persons)

Copies to:

Damien Zoubek, Esq.

Jenny Hochenberg, Esq.

Freshfields US LLP

3 World Trade Center

175 Greenwich Street

New York, NY 10007

(212) 277-4000

Lars Meyer

Freshfields PartG mbB

Große Gallusstraße 14

60315 Frankfurt am Main

Germany

+49 69 273080

☒ Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

Check the appropriate boxes below to designate any transactions to which the statement relates:

☒ 

third-party tender offer subject to Rule 14d-1.

☐ 

issuer tender offer subject to Rule 13e-4.

☐ 

going-private transaction subject to Rule 13e-3.

☐ 

amendment to Schedule 13D under Rule 13d-2.

Check the following box if the filing is a final amendment reporting the results of the tender offer. ☐

If applicable, check the appropriate box(es) below to designate the appropriate rule provision(s) relied upon:

☐ 

Rule 13e-4(i) (Cross-Border Issuer Tender Offer)

☐ 

Rule 14d-1(d) (Cross-Border Third-Party Tender Offer)

This Tender Offer Statement on Schedule TO relates solely to preliminary communications made before the commencement of a planned tender offer for all outstanding shares of Class A Common Stock, par value $0.01 per share, and Class B Common Stock, par value $0.01 per share, of Rapid Micro Biosystems, Inc., a Delaware corporation ("Rapid"), by EMD Holdings NewCo II, Inc, a Delaware corporation ("Purchaser") and a wholly owned subsidiary of Merck KGaA, Darmstadt, Germany, a German corporation with general partners ("Parent") to be commenced pursuant to the Agreement and Plan of Merger, dated as of November 16, 2026, by and among Rapid, Parent and Purchaser.

Additional Information and Where to Find It

The tender offer described in this communication has not yet commenced, and this communication is neither an offer to purchase nor a solicitation of an offer to sell securities. At the time the tender offer is commenced, Parent and Purchaser will file a tender offer statement on Schedule TO with the U.S. Securities and Exchange Commission (the "SEC"), and Rapid will file a solicitation/recommendation statement on Schedule 14D-9 with the SEC. INVESTORS AND SECURITY HOLDERS ARE STRONGLY ADVISED TO READ THE TENDER OFFER STATEMENT (INCLUDING AN OFFER TO PURCHASE, LETTER OF TRANSMITTAL AND RELATED TENDER OFFER DOCUMENTS) THAT WILL BE FILED BY PARENT AND PURCHASER WITH THE SEC AND THE RELATED SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 THAT WILL BE FILED BY RAPID WITH THE SEC, WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. These materials (once they become available) will be made available to Rapid shareholders at no cost by the information agent for the tender offer. Once filed, these documents will be available at no charge on the SEC's website at www.sec.gov. In addition, a copy of the offer to purchase, letter of transmittal and certain other related tender offer documents (once they become available) may be obtained free of charge from Parent under the "Investors" section of Parent's website at https://www.emdgroup.com/en. A copy of the solicitation/recommendation statement (once it becomes available) also may be obtained free of charge from Rapid under the "Investor Relations" section of Rapid's website at https://www.rapidmicrobio.com/.

Forward Looking Statements

This Tender Offer Statement includes "forward-looking statements" regarding the potential acquisition of Rapid. All statements, other than statements of historical fact, may be forward-looking statements. These forward-looking statements may be accompanied by such words as "outlook," "aim," "anticipate," "assume," "believe," "contemplate," "continue," "could," "due," "estimate," "expect," "goal," "intend," "may," "objective," "plan," "predict," "potential," "positioned," "seek," "should," "target," "will," "would" and other words and terms of similar meaning.

Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those currently anticipated due to a number of risks and uncertainties.

Risks and uncertainties include, but are not limited to: the risk that the closing conditions for the proposed acquisition will not be satisfied; uncertainty as to the percentage of Rapid shareholders that will support the proposed acquisition and tender their shares in the offer; the risk of shareholder litigation relating to the proposed acquisition, including resulting expense or delay; the possibility that the proposed acquisition will not be completed in the expected timeframe or at all; potential adverse effects to the businesses of Parent or Rapid during the pendency of the proposed acquisition, such as employee departures or distraction of management from business operations; the potential that the expected benefits and opportunities of the proposed acquisition, if completed, may not be realized or may take longer to realize than expected; the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement and potential adverse reactions or changes to business relationships resulting from the proposed acquisition, including the effect of the acquisition on the ability to maintain key vendor, supplier or partner relationships; and risks related to the integration of Rapid into Parent subsequent to the closing of the proposed acquisition and the timing of such integration.

A further list and descriptions of these risks, uncertainties and other factors can be found in Parent's public reports which are available on the Parent's website at https://www.emdgroup.com/en. Parent is not under any obligation, and expressly disclaims any obligation, to update or otherwise revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Item 12. Exhibits.

Exhibit

Description

99.1 Press Release, dated November 16, 2026.
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

2

Merck KGaA published this content on November 16, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on November 16, 2026 at 22:15 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]